წყაროები
ძირითადი სტატიები
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-23.სრული ტექსტი აბსტრაქტი
National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. Oct 2020 [internet publication].სრული ტექსტი
Smolen JS, Landewé RBM, Bergstra SA, eta al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18 Epub 2022 Nov 10.სრული ტექსტი აბსტრაქტი
გამოყენებული სტატიები
1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001 Sep 15;358(9285):903-11. აბსტრაქტი
2. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1316-22. აბსტრაქტი
3. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019 Nov;78(11):1463-71. აბსტრაქტი
4. Almutairi KB, Nossent JC, Preen DB, et al. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021 May;48(5):669-76. აბსტრაქტი
5. Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol. 2001 Mar;15(1):139-70. აბსტრაქტი
6. Kavanaugh AF. Rheumatoid arthritis in the elderly: is it a different disease? Am J Med. 1997 Dec 29;103(6A):40-8S. აბსტრაქტი
7. Yazici Y, Paget SA. Elderly-onset rheumatoid arthritis. Rheum Dis Clin North Am. 2000 Aug;26(3):517-26. აბსტრაქტი
8. Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur). 2010 Dec;5(4):286-91.სრული ტექსტი აბსტრაქტი
9. Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017 Sep;37(9):1551-7. აბსტრაქტი
10. Ye D, Mao Y, Xu Y, et al. Lifestyle factors associated with incidence of rheumatoid arthritis in US adults: analysis of National Health and Nutrition Examination Survey database and meta-analysis. BMJ Open. 2021 Jan 26;11(1):e038137.სრული ტექსტი აბსტრაქტი
11. Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2010 Jan;69(1):70-81. აბსტრაქტი
12. Källberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011 Mar;70(3):508-11.სრული ტექსტი აბსტრაქტი
13. Hutchinson D, Shepstone L, Moots R, et al. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Ann Rheum Dis. 2001 Mar;60(3):223-7.სრული ტექსტი აბსტრაქტი
14. Abhishek A, Doherty M, Kuo CF, et al. Rheumatoid arthritis is getting less frequent - results of a nationwide population-based cohort study. Rheumatology (Oxford). 2017 May 1;56(5):736-44.სრული ტექსტი აბსტრაქტი
15. Uhlig T, Kvien TK. Is rheumatoid arthritis disappearing? Ann Rheum Dis. 2005 Jan;64(1):7-10.სრული ტექსტი აბსტრაქტი
16. Salari N, Kazeminia M, Shohaimi S, et al. Socioeconomic inequality in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2021 Nov;40(11):4511-25.სრული ტექსტი აბსტრაქტი
17. Frisell T, Saevarsdottir S, Askling J. Family history of rheumatoid arthritis: an old concept with new developments. Nat Rev Rheumatol. 2016 Jun;12(6):335-43. აბსტრაქტი
18. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987 Nov;30(11):1205-13. აბსტრაქტი
19. van der Helm-van Mil AH, Huizinga TW, de Vries RR, et al. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis Rheum. 2007 Jun;56(6):1728-35. აბსტრაქტი
20. Mustelin T, Bottini N, Stanford SM. The contribution of PTPN22 to rheumatic disease. Arthritis Rheumatol. 2019 Mar 2;71(4):486-95. აბსტრაქტი
21. Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med. 2023 Feb 9;388(6):529-42.სრული ტექსტი აბსტრაქტი
22. Chen P, Li Y, Li L, et al. Association between the interleukin (IL)-17A rs2275913 polymorphism and rheumatoid arthritis susceptibility: a meta-analysis and trial sequential analysis. J Int Med Res. 2021 Oct;49(10):3000605211053233.სრული ტექსტი აბსტრაქტი
23. Pacheco-Soto BT, Porchia LM, Lara-Vazquez WC, et al. The association between interleukin-6 promoter polymorphisms and rheumatoid arthritis by ethnicity: a meta-analysis of 33 studies. Reumatol Clin (Engl Ed). 2021 Oct;17(8):447-55.სრული ტექსტი აბსტრაქტი
24. Agonia I, Couras J, Cunha A, et al. IL-17, IL-21 and IL-22 polymorphisms in rheumatoid arthritis: a systematic review and meta-analysis. Cytokine. 2020 Jan;125:154813.სრული ტექსტი აბსტრაქტი
25. Shao M, Xie H, Yang H, et al. Association of interleukin-6 promoter polymorphism with rheumatoid arthritis: a meta-analysis with trial sequential analysis. Clin Rheumatol. 2022 Feb;41(2):411-9.სრული ტექსტი აბსტრაქტი
26. Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am J Manag Care. 2014 May;20(7 suppl):S128-35.სრული ტექსტი აბსტრაქტი
27. Ishikawa Y, Terao C. The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review. Cells. 2020 Feb 19;9(2).სრული ტექსტი აბსტრაქტი
28. Karlson EW, Chang SC, Cui J, et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis. 2010 Jan;69(1):54-60.სრული ტექსტი აბსტრაქტი
29. Too CL, Yahya A, Murad S, et al. Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther. 2012 Apr 26;14(2):R89.სრული ტექსტი აბსტრაქტი
30. Li X, Zhu J, Zhao W, et al. The causal effect of obesity on the risk of 15 autoimmune diseases: a mendelian randomization study. Obes Facts. 2023;16(6):598-605.სრული ტექსტი აბსტრაქტი
31. Khanna D, Khanna S, Khanna P, et al. Obesity: a chronic low-grade inflammation and its markers. Cureus. 2022 Feb;14(2):e22711.სრული ტექსტი აბსტრაქტი
32. Deane KD, Demoruelle MK, Kelmenson LB, et al. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017 Sep 18;31(1):3-18.სრული ტექსტი აბსტრაქტი
33. Batool A, Vaithilingam RD, Mohamad Hassan NH, et al. Evaluating the potential of matrix metalloproteinase as a diagnostic biomarker in rheumatoid arthritis and periodontitis: a systematic review and meta-analysis. Medicine (Baltimore). 2023 Oct 13;102(41):e35340.სრული ტექსტი აბსტრაქტი
34. Jaśkiewicz Ł, Chmielewski G, Kuna J, et al. The role of sclerostin in rheumatic diseases: a review. J Clin Med. 2023 Sep 28;12(19).სრული ტექსტი აბსტრაქტი
35. Mao YM, Liao T, Ye QL, et al. Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis. Z Rheumatol. 2023 Jan;82(suppl 1):51-8.სრული ტექსტი აბსტრაქტი
36. Bottazzi B, Inforzato A, Messa M, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016 Jun;64(6):1416-27.სრული ტექსტი აბსტრაქტი
37. Zlibut A, Bocsan IC, Agoston-Coldea L. Pentraxin-3 and endothelial dysfunction. Adv Clin Chem. 2019;91:163-79.სრული ტექსტი აბსტრაქტი
38. Guan SY, Chen Y, Shao M, et al. Increased circulating pentraxin 3 levels in patients with rheumatoid arthritis: a meta-analysis. Curr Pharm Des. 2022;28(27):2260-9.სრული ტექსტი აბსტრაქტი
39. Frisell T, Holmqvist M, Källberg H, et al. Familial risks and heritability of rheumatoid arthritis: role of rheumatoid factor/anti-citrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum. 2013 Nov;65(11):2773-82.სრული ტექსტი აბსტრაქტი
40. Giri PS, Dwivedi M. Meta-analysis for association of interleukin 4 VNTR polymorphism with rheumatoid arthritis risk and severity. Biochem Genet. 2023 Jun;61(3):823-46.სრული ტექსტი აბსტრაქტი
41. Bagheri-Hosseinabadi Z, Imani D, Yousefi H, et al. Vitamin D receptor (VDR) gene polymorphism and risk of rheumatoid arthritis (RA): systematic review and meta-analysis. Clin Rheumatol. 2020 Dec;39(12):3555-69.სრული ტექსტი აბსტრაქტი
42. Zhu L, Chen P, Sun X, et al. Associations between polymorphisms in the IL-1 gene and the risk of rheumatoid arthritis and systemic lupus erythematosus: evidence from a meta-analysis. Int Arch Allergy Immunol. 2021;182(3):234-42.სრული ტექსტი აბსტრაქტი
43. Zhang X, Zhang X, Yang Y, et al. Association between passive smoking and the risk of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023 Mar;42(3):663-72.სრული ტექსტი აბსტრაქტი
44. Rakieh C, Nam JL, Hunt L, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2015 Sep;74(9):1659-66. აბსტრაქტი
45. Nam JL, Hunt L, Hensor EM, et al. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study. Ann Rheum Dis. 2016 Aug;75(8):1452-6. აბსტრაქტი
46. Cope AP, Jasenecova M, Vasconcelos JC, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024 Mar 2;403(10429):838-49.სრული ტექსტი აბსტრაქტი
47. Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024 Mar 2;403(10429):850-9.სრული ტექსტი აბსტრაქტი
48. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81.სრული ტექსტი აბსტრაქტი
49. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-23.სრული ტექსტი აბსტრაქტი
50. National Rheumatoid Arthritis Society. What is RA? May 2015 [internet publication].სრული ტექსტი
51. Aho K, Palusuo T, Kurki P. Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum. 1994 Jun;23(6):379-87. აბსტრაქტი
52. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000;2(3):236-43. აბსტრაქტი
53. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004 Mar;50(3):709-15. აბსტრაქტი
54. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol. 1994 Jul;21(7):1227-37. აბსტრაქტი
55. Mohan C, Assassi S. Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? BMJ. 2015 Nov 26;351:h5079. აბსტრაქტი
56. Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72:804-814. აბსტრაქტი
57. American College of Radiology. ACR appropriateness criteria®: chronic extremity joint pain - suspected inflammatory arthritis. 2022 [internet publication].სრული ტექსტი აბსტრაქტი
58. Takase-Minegishi K, Horita N, Kobayashi K, et al. Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2018 Jan 1;57(1):49-58.სრული ტექსტი აბსტრაქტი
59. Lage-Hansen PR, Lindegaard H, Chrysidis S, et al. The role of ultrasound in diagnosing rheumatoid arthritis, what do we know? An updated review. Rheumatol Int. 2017 Feb;37(2):179-87. აბსტრაქტი
60. Freeston JE, Wakefield RJ, Conaghan PG, et al. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis. 2010 Feb;69(2):417-9. [Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.] აბსტრაქტი
61. Simpson E, Hock E, Stevenson M, et al. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technol Assess. 2018 Apr;22(20):1-258.სრული ტექსტი აბსტრაქტი
62. National Institute for Health and Care Excellence. Rheumatoid arthritis in adults: management. Oct 2020 [internet publication].სრული ტექსტი
63. van der Heijde DM, van 't Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993 Mar;20(3):579-81. აბსტრაქტი
64. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8. აბსტრაქტი
65. Pincus T, Yazici Y, Bergman M, et al. A proposed approach to recognise "near-remission" quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a "continuous quality improvement". Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-60-5. აბსტრაქტი
66. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012 May;64(5):640-7.სრული ტექსტი აბსტრაქტი
67. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007 Mar 20;146(6):406-15. აბსტრაქტი
68. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430):263-9. აბსტრაქტი
69. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011 Jun;70(6):1039-46. აბსტრაქტი
70. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011 Mar;63(3):633-9.სრული ტექსტი აბსტრაქტი
71. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24.სრული ტექსტი აბსტრაქტი
72. Allen A, Carville S, McKenna F, et al. Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance. BMJ. 2018 Aug 3;362:k3015. აბსტრაქტი
73. Efthimiou P, Kontzias A, Hur P, et al. Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021 Aug;51(4):858-74.სრული ტექსტი აბსტრაქტი
74. Franchini S, Dagna L, Salvo F, et al. Adult onset Still's disease: clinical presentation in a large cohort of Italian patients. Clin Exp Rheumatol. 2010 Jan-Feb;28(1):41-8.სრული ტექსტი აბსტრაქტი
75. Hu QY, Zeng T, Sun CY, et al. Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 121(6):52-7.სრული ტექსტი აბსტრაქტი
76. Liu Z, Lv X, Tang G. Clinical features and prognosis of adult-onset Still's disease: 75 cases from China. Int J Clin Exp Med. 2015;8(9):16634-9.სრული ტექსტი აბსტრაქტი
77. Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. Clin Exp Rheumatol. 2011 Mar-Apr;29(2):331-6.სრული ტექსტი აბსტრაქტი
78. Zeng T, Zou YQ, Wu MF, et al. Clinical features and prognosis of adult-onset still's disease: 61 cases from China. J Rheumatol. 2009 May;36(5):1026-31.სრული ტექსტი აბსტრაქტი
79. Chen DY, Lan JL, Hsieh TY, et al. Clinical manifestations, disease course, and complications of adult-onset Still's disease in Taiwan. J Formos Med Assoc. 2004 Nov;103(11):844-52.სრული ტექსტი აბსტრაქტი
80. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun. 2018 Sep;93:24-36.სრული ტექსტი აბსტრაქტი
81. Mitrovic S, Fautrel B. New markers for adult-onset still's disease. Joint Bone Spine. 2018 May;85(3):285-93.სრული ტექსტი აბსტრაქტი
82. Vordenbäumen S, Feist E, Rech J, et al. Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline. Z Rheumatol. 2023 Feb;82(suppl 2):81-92.სრული ტექსტი აბსტრაქტი
83. Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016 Jun 30;374(26):2575-84.სრული ტექსტი აბსტრაქტი
84. Tedeschi SK, Becce F, Pascart T, et al. Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an iInternational Multidisciplinary Working Group. Arthritis Care Res (Hoboken). 2023 Apr;75(4):825-34.სრული ტექსტი აბსტრაქტი
85. Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-5.სრული ტექსტი აბსტრაქტი
86. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-86.სრული ტექსტი აბსტრაქტი
87. Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol. 2023 Jan;75(1):15-22.სრული ტექსტი აბსტრაქტი
88. Smolen JS, Landewé RBM, Bergstra SA, eta al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18 Epub 2022 Nov 10.სრული ტექსტი აბსტრაქტი
89. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1986 Oct;13(5):841-5. აბსტრაქტი
90. Curtis JR, Emery P, Karis E, et al. Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission. Arthritis Rheumatol. 2021 May;73(5):759-68.სრული ტექსტი აბსტრაქტი
91. Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial. JAMA. 2021 May 4;325(17):1755-64.სრული ტექსტი აბსტრაქტი
92. Meng CF, Rajesh DA, Jannat-Khah DP, et al. Can patients with controlled rheumatoid arthritis taper methotrexate from targeted therapy and sustain remission? a systematic review and metaanalysis. J Rheumatol. 2023 Jan;50(1):36-47.სრული ტექსტი აბსტრაქტი
93. Wang X, Tang Z, Huang T, et al. Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis. Rheumatology (Oxford). 2023 Apr 3;62(4):1410-16.სრული ტექსტი აბსტრაქტი
94. Vasconcelos LB, Silva MT, Galvao TF. Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2020 Dec;40(12):1949-59.სრული ტექსტი აბსტრაქტი
95. D Vinson, LM Benhamou, Y Degboé, et al. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. Arthritis Research & Therapy. 2020 Apr 29;22(1):97.სრული ტექსტი
96. Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Ann Rheum Dis. 2023 Nov;82(11):1394-403.სრული ტექსტი აბსტრაქტი
97. Palmowski A, Pankow A, Terziyska K, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024 Feb;64:152349.სრული ტექსტი აბსტრაქტი
98. Xu J, Xiao L, Zhu J, et al. Methotrexate use reduces mortality risk in rheumatoid arthritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2022 Aug;55:152031.სრული ტექსტი აბსტრაქტი
99. ter Wee MM, den Uyl D, Boers M, et al. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis. 2015 Jun;74(6):1233-40. აბსტრაქტი
100. Ota R, Hata T, Hirata A, et al. Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: a retrospective cohort study. Br J Clin Pharmacol. 2023 Jul;89(7):2168-78.სრული ტექსტი აბსტრაქტი
101. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014 Aug;73(8):1549-51.სრული ტექსტი აბსტრაქტი
102. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009 Aug 8;374(9688):459-66. აბსტრაქტი
103. Bijlsma JW, Welsing PM, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016 Jul 23;388(10042):343-55. აბსტრაქტი
104. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015 Jun;74(6):1037-44.სრული ტექსტი აბსტრაქტი
105. Donahue KE, Gartlehner G, Schulman ER, et al. Drug therapy for early rheumatoid arthritis: a systematic review update. Jul 2018 [internet publication].სრული ტექსტი აბსტრაქტი
106. Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2018 Nov 19;15(1):13-25. აბსტრაქტი
107. Tarp S, Jørgensen TS, Furst DE, et al. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2019 Jun;48(6):958-66.სრული ტექსტი აბსტრაქტი
108. Lend K, Koopman FA, Lampa J, et al. Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: a post hoc analysis of a randomized controlled trial. Arthritis Rheumatol. 2024 Mar;76(3):363-76.სრული ტექსტი აბსტრაქტი
109. Nayebirad S, Javinani A, Javadi M, et al. The effect of smoking on response to methotrexate in rheumatoid arthritis patients: a systematic review and meta-analysis. Mod Rheumatol. 2023 Dec 22;34(1):68-78.სრული ტექსტი აბსტრაქტი
110. Lee YH, Bae SC. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis: meta-analysis of randomized controlled trials. Z Rheumatol. 2017 Aug;76(6):528-34. აბსტრაქტი
111. Schmitz S, Adams R, Walsh CD, et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012 Feb;71(2):225-30. აბსტრაქტი
112. Murray E, Ellis A, Butylkova Y, et al. Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis. J Comp Eff Res. 2018 Oct;7(10):959-74.სრული ტექსტი აბსტრაქტი
113. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. Jul 2021 [internet publication].სრული ტექსტი
114. Ji X, Hu L, Wang Y, et al. Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. Chin Med J (Engl). 2022 Jan 12;135(4):409-15.სრული ტექსტი აბსტრაქტი
115. Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208-32. აბსტრაქტი
116. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun;76(6):1101-36.სრული ტექსტი აბსტრაქტი
117. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011 Jun;63(6):1479-85.სრული ტექსტი აბსტრაქტი
118. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015 Jun;74(6):1087-93.სრული ტექსტი აბსტრაქტი
119. Bonovas S, Minozzi S, Lytras T, et al. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54. აბსტრაქტი
120. Wetzman A, Lukas C, Gaujoux-Viala C, et al. Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis. Arthritis Care Res (Hoboken). 2023 Feb;75(2):260-71.სრული ტექსტი აბსტრაქტი
121. Xie W, Xiao S, Huang Y, et al. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford). 2020 May 1;59(5):930-9.სრული ტექსტი აბსტრაქტი
122. Wang JL, Yin WJ, Zhou LY, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2020 Mar;39(3):769-78.სრული ტექსტი აბსტრაქტი
123. Verhoef LM, van den Bemt BJ, van der Maas A, et al. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2019 May 24;(5):CD010455.სრული ტექსტი აბსტრაქტი
124. Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis. 2018 Apr;77(4):515-22. აბსტრაქტი
125. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015 Jun;67(6):1424-37.სრული ტექსტი აბსტრაქტი
126. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014 Sep;73(9):1626-34.სრული ტექსტი აბსტრაქტი
127. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun;75(6):1081-91.სრული ტექსტი აბსტრაქტი
128. Sung YK, Lee YH. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021 Sep;59(9):618-26.სრული ტექსტი აბსტრაქტი
129. Sung YK, Lee YH. Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: a bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Jan;60(1):13-23.სრული ტექსტი აბსტრაქტი
130. Choy E, Freemantle N, Proudfoot C, et al. Indirect treatment comparison of the efficacy and safety of sarilumab monotherapy in rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs. Adv Ther. 2019 Apr;36(4):817-27.სრული ტექსტი აბსტრაქტი
131. Sanmarti R, Veale DJ, Martin-Mola E, et al. Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial. Arthritis Rheumatol. 2019 Oct;71(10):1616-25. აბსტრაქტი
132. Bilal J, Berlinberg A, Riaz IB, et al. Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019 Oct 2;2(10):e1913102.სრული ტექსტი აბსტრაქტი
133. Lambert N, Hansen I, El Moussaoui M, et al. Lung and liver sarcoidosis-like reaction induced by tocilizumab. Br J Clin Pharmacol. 2021 Apr 26 [Epub ahead of print]. აბსტრაქტი
134. Ko PH, Kuo MH, Kao IT, et al. The risk of hepatitis B virus reactivation in rheumatoid arthritis patients receiving tocilizumab: a systematic review and meta-analysis. Viruses. 2024 Jan 3;16(1).სრული ტექსტი აბსტრაქტი
135. Katelani S, Fragoulis GE, Bakasis AD, et al. HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis. Rheumatology (Oxford). 2023 Oct 23;62(si3):SI252-9.სრული ტექსტი აბსტრაქტი
136. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2019. Oct 2019 [internet publication].სრული ტექსტი
137. Medicines and Healthcare products Regulatory Agency. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation. Jul 2019 [internet publication].სრული ტექსტი
138. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009 Dec;68(12):1870-7. აბსტრაქტი
139. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28-38.სრული ტექსტი აბსტრაქტი
140. Mohamed Ahamada M, Wu X. Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis. Clin Exp Rheumatol. 2023 Sep;41(9):1882-900.სრული ტექსტი აბსტრაქტი
141. Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan;74(1):19-26.სრული ტექსტი აბსტრაქტი
142. Hetland ML, Haavardsholm EA, Rudin A, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020 Dec 2;371:m4328.სრული ტექსტი აბსტრაქტი
143. Westhovens R, Robles M, Ximenes AC, et al. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis. 2015 Mar;74(3):564-8.სრული ტექსტი აბსტრაქტი
144. Emery P, Burmester GR, Bykerk VP, et al. Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open. 2019;5(1):e000840.სრული ტექსტი აბსტრაქტი
145. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Sep 2021 [internet publication].სრული ტექსტი
146. ClinicalTrials.gov. Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis (A3921133). NCT02092467. Aug 2021 [internet publication].სრული ტექსტი
147. European Medicines Agency. Janus kinase inhibitors (JAKi). Jan 2023 [internet publication].სრული ტექსტი
148. Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2023 Feb;10(1):201-23.სრული ტექსტი აბსტრაქტი
149. National Institute for Health and Care Excellence. Filgotinib for treating moderate to severe rheumatoid arthritis. Feb 2021 [internet publication].სრული ტექსტი
150. National Institute for Health and Care Excellence. Upadacitinib for treating severe rheumatoid arthritis. Dec 2020 [internet publication].სრული ტექსტი
151. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002 Jan 1;136(1):1-12. აბსტრაქტი
152. Pincus T, Huizinga TW, Yazici Y. N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol. 2007 Feb;34(2):250-2. აბსტრაქტი
153. Pincus T, Sokka T, Stein CM. Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med. 2002 Jan 1;136(1):76-8. აბსტრაქტი
154. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006 May;54(5):1401-9.სრული ტექსტი აბსტრაქტი
155. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012 Mar 6;156(5):329-39.სრული ტექსტი აბსტრაქტი
156. Safy M, Jacobs J, IJff ND, et al; Society for Rheumatology Research Utrecht (SRU). Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis. 2017 Aug;76(8):1432-5. აბსტრაქტი
157. Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015 Jan;74(1):27-34. აბსტრაქტი
158. Adami G, Fassio A, Rossini M, et al. Bone loss in inflammatory rheumatic musculoskeletal disease patients treated with low-dose glucocorticoids and prevention by anti-osteoporosis medications. Arthritis Rheumatol. 2023 Oct;75(10):1762-9.სრული ტექსტი აბსტრაქტი
159. Palmowski A, Nielsen SM, Boyadzhieva Z, et al. The effect of low-dose glucocorticoids over two years on weight and blood pressure in rheumatoid arthritis: individual patient data from five randomized trials. Ann Intern Med. 2023 Sep;176(9):1181-9.სრული ტექსტი აბსტრაქტი
160. Burmester GR, Buttgereit F, Bernasconi C, et al. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020 Jul 25;396(10246):267-76. აბსტრაქტი
161. Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013 Feb;72(2):204-10.სრული ტექსტი აბსტრაქტი
162. Blavnsfeldt AG, de Thurah A, Thomsen MD, et al. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials. Bone. 2018 Sep;114:172-80. აბსტრაქტი
163. David P, Di Matteo A, Hen O, et al. Poly-refractory rheumatoid arthritis: an uncommon subset of difficult to treat disease with distinct inflammatory and noninflammatory phenotypes. Arthritis Rheumatol. 2024 Apr;76(4):510-21.სრული ტექსტი აბსტრაქტი
164. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan;54(1):26-37. აბსტრაქტი
165. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006 Mar;54(3):702-10. აბსტრაქტი
166. Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81. აბსტრაქტი
167. Janke K, Biester K, Krause D, et al. Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ. 2020 Jul 7;370:m2288.სრული ტექსტი აბსტრაქტი
168. Carmona L, Ortiz A, Abad MA. How good is to switch between biologics? A systematic review of the literature. Acta Reumatol Port. 2007 Apr-Jun;32(2):113-28. აბსტრაქტი
169. Wells AF, Curtis JR, Betts KA, et al. Systematic literature review and meta-analysis of tumor necrosis factor-alpha experienced rheumatoid arthritis. Clin Ther. 2017 Jul 20;39(8):1680-94.e2. აბსტრაქტი
170. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 Jan;72(1):43-50.სრული ტექსტი აბსტრაქტი
171. Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495-507.სრული ტექსტი აბსტრაქტი
172. Gottenberg JE, Morel J, Perrodeau E, et al; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 2019 Jan 24;364:l67.სრული ტექსტი აბსტრაქტი
173. Källmark H, Einarsson JT, Nilsson JÅ, et al. Sustained remission in patients with rheumatoid arthritis receiving triple therapy compared to biologic therapy: a Swedish Nationwide Register study. Arthritis Rheumatol. 2021 Jul;73(7):1135-44.სრული ტექსტი აბსტრაქტი
174. Mazouyès A, Clay M, Bernard AC, et al. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: meta-analysis of randomized controlled trials. Joint Bone Spine. 2016 Dec 15;84(5):563-70. აბსტრაქტი
175. Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007 Jun;29(2):185-91. აბსტრაქტი
176. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2017 Oct 13;77(2):228-33.სრული ტექსტი აბსტრაქტი
177. Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021 Jan 23;397(10271):305-17.სრული ტექსტი აბსტრაქტი
178. Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022 Aug 25;387(8):715-26.სრული ტექსტი აბსტრაქტი
179. Abuelazm M, Ghanem A, Mahmoud A, et al. The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis. Clin Rheumatol. 2023 Jun;42(6):1503-20.სრული ტექსტი აბსტრაქტი
180. Mahmoud AM. Olokizumab's effectiveness and safety in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. J Clin Densitom. 2023 Jan-Mar;26(1):61-82.სრული ტექსტი აბსტრაქტი
181. Lee YH, Song GG. Comparative efficacy and safety of peficitinib 25, 50, 100, and 150 mg in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials. Clin Drug Investig. 2020 Jan;40(1):65-72.სრული ტექსტი აბსტრაქტი
182. Lee YH, Song GG. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: a bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2020 Jul;23(7):868-75.სრული ტექსტი აბსტრაქტი
183. Yang Y, Li J, Liu J, et al. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study. Lancet Reg Health West Pac. 2024 Jan;42:100925.სრული ტექსტი აბსტრაქტი
184. Wolfe F, Rasker JJ, Boers M, et al. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007 Aug 15;57(6):935-42. აბსტრაქტი
185. Pincus T, Chung C, Segurado OG, et al. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov;33(11):2146-52. აბსტრაქტი
186. Pincus T, Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S1-9. აბსტრაქტი
187. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol. 2007 Aug;21(4):663-75. აბსტრაქტი
188. Stevens JC, Beard CM, O'Fallon WM, et al. Conditions associated with carpal tunnel syndrome. Mayo Clin Proc. 1992 Jun;67(6):541-8. აბსტრაქტი
189. Geoghegan JM, Clark DI, Bainbridge LC, et al. Risk factors in carpal tunnel syndrome. J Hand Surg Br. 2004 Aug;29(4):315-20. აბსტრაქტი
190. ter Wee MM, Lems WF, Usan H, et al. The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review. Ann Rheum Dis. 2012 Feb;71(2):161-71. აბსტრაქტი
191. Hansen PR, Feineis M, Abdulla J. Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: a systematic literature review and meta-analysis. Eur J Intern Med. 2019 Apr;62:72-9. აბსტრაქტი
192. Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018 Sep 4;70(10):1544-54. აბსტრაქტი
193. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum. 2003 Oct;48(10):2769-72. აბსტრაქტი
194. Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines? J Rheumatol. 2002 Aug;29(8):1586-9. აბსტრაქტი
195. England BR, Smith BJ, Baker NA, et al. 2022 American College of Rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Rheumatol. 2023 Aug;75(8):1299-311.სრული ტექსტი აბსტრაქტი
ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას